The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO 2015 | Design and results of pacritinib for myelofibrosis trial (PERSIST-1)

Name: Design and results of pacritinib for myelofibrosis trial (PERSIST-1)
Uploaded: 2015-06-02T00:00:00.000Z
Duration: 1 min 45 s
Description: Dr Jean-Jacques Kiladjian, at the 2015 American Society of Clinical Oncology (ASCO), describes the design and recent results of the PERSIST- 1 trial of pacritinib for patients with myelofibrosis, with specific focus on the impact on thrombocytopenia, low-platelet count, and transfusion independence.

Jean-Jacques Kiladjian • 2 Jun 2015

ASCO 2015

Myeloproliferative Neoplasms Pacritinib

PERSIST-1

Dr Jean-Jacques Kiladjian, at the 2015 American Society of Clinical Oncology (ASCO), describes the design and recent results of the PERSIST- 1 trial of pacritinib for patients with myelofibrosis, with specific focus on the impact on thrombocytopenia, low-platelet count, and transfusion independence.